Janux Therapeutics, Inc.
JANX
$25.26
-$1.74-6.43%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 439.00K | 8.90M | 1.25M | 2.46M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 439.00K | 8.90M | 1.25M | 2.46M |
| Cost of Revenue | 20.81M | 18.61M | 14.90M | 14.07M | 12.24M |
| Gross Profit | -20.81M | -18.18M | -6.00M | -12.82M | -9.78M |
| SG&A Expenses | 8.22M | 17.67M | 7.82M | 7.34M | 6.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.02M | 36.28M | 22.72M | 21.41M | 18.60M |
| Operating Income | -29.02M | -35.84M | -13.82M | -20.16M | -16.14M |
| Income Before Tax | -20.22M | -28.06M | -5.96M | -14.76M | -11.76M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.22M | -28.06M | -5.96M | -14.76M | -11.76M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.22M | -28.06M | -5.96M | -14.76M | -11.76M |
| EBIT | -29.02M | -35.84M | -13.82M | -20.16M | -16.14M |
| EBITDA | -28.51M | -35.33M | -13.32M | -19.63M | -15.61M |
| EPS Basic | -0.36 | -0.51 | -0.11 | -0.30 | -0.25 |
| Normalized Basic EPS | -0.22 | -0.32 | -0.07 | -0.19 | -0.16 |
| EPS Diluted | -0.36 | -0.51 | -0.11 | -0.30 | -0.25 |
| Normalized Diluted EPS | -0.22 | -0.32 | -0.07 | -0.19 | -0.16 |
| Average Basic Shares Outstanding | 56.83M | 54.63M | 54.45M | 49.05M | 46.68M |
| Average Diluted Shares Outstanding | 56.83M | 54.63M | 54.45M | 49.05M | 46.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
